Skip to search formSkip to main contentSkip to account menu

CEOP-IMVP-Dexa regimen

National Institutes of Health

Related topics

Related topics

9 relations

Broader (9)

Antineoplastic Combined Chemotherapy ProtocolsCyclophosphamideDexamethasoneEpirubicin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Erratum to: Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin’s lymphoma (NHL…
2012
2012
Impact of cutoff age in predicting clinical outcomes of elderly diffuse large B cell lymphoma receiving rituximab or not: A hospital-based study
2008
2008
A152 CEOP-HE・AEGISに向けたチベット・ヒマラヤ研究の動向(スペシャル・セッション「GAMEからMAHASRIへ〜モンスーン研究の進展と今後〜」)
2005
2005
Long-term results of dose density therapy in patients with aggressive lymphoma
To evaluate the long-term outcome of dose density chemotherapy in the treatment of aggressive lymphoma, we analyzed 142 patients… 
2004
2004
African Burkitt lymphoma successfully treated with CEOP polychemotherapy.
Review
1998
Review
1998
Chemotherapy in patients with acquired immunodeficiency virus syndrome associated with non-Hodgkin's lymphoma.
We retrospectively analyzed our chemotherapy results in patients with the Acquired Immunodeficiency Virus syndrome (AIDS) and… 
1997
1997
Randomized open label phase III trial of CEOP/IMVP-Dexa alternating chemotherapy and filgrastim versus CEOP/IMVP-Dexa alternating chemotherapy for aggressive non-Hodgkin’s lymphoma (NHL). A multi…
Primary end point of this trial was to reduce neutropenic infections during the treatment of aggressive NHL with CEOP/IMVP-Dexa… 
1996
1996
CEOP-IMVP-Dexa in the treatment of aggressive lymphomas: an Austrian multicenter trial.
PURPOSE This trial evaluated the efficacy, toxicity, and practicability of a new intensive chemotherapy regimen in a multicenter… 
1995
1995
Malabsorption associated with a high-grade-malignant non-Hodgkin's lymphoma, alpha-heavy-chain disease and immunoproliferative small intestinal disease.
We report on a 28 year old Turkish woman, who was admitted to our hospital with the symptoms of malabsorption and protein-loosing… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)